When to Hold Midodrine Based on Supine Systolic Blood Pressure
Midodrine should be held if supine systolic blood pressure reaches or exceeds 180 mmHg, as this represents clinically significant supine hypertension that increases cardiovascular risk, particularly stroke. 1
Monitoring Requirements
The FDA label explicitly states that supine and standing blood pressure must be monitored regularly, and midodrine administration should be stopped if supine blood pressure increases excessively 1. The most potentially serious adverse reaction is marked elevation of supine arterial blood pressure, with systolic pressures of approximately 200 mmHg observed in about 13.4% of patients on 10 mg doses 1.
Specific Blood Pressure Thresholds
Pre-treatment exclusion: Patients with pre-existing sustained supine hypertension above 180/110 mmHg were routinely excluded from clinical trials, and use in such patients is not recommended 1
During treatment: The FDA label specifies the titration endpoint should maintain supine pressure below 180/100 mmHg 1
Uncontrolled hypertension warning: The label explicitly warns that uncontrolled hypertension increases the risk of cardiovascular events, particularly stroke 1
Practical Monitoring Algorithm
- Check supine blood pressure before each dose and regularly during maintenance therapy
- Hold the dose if supine systolic ≥180 mmHg or diastolic ≥100 mmHg
- Discontinue therapy if supine hypertension persists or worsens despite dose adjustments
- Reassess need for continued therapy if patients do not show symptomatic improvement, as the drug should only be continued in those who attain symptomatic benefit 1
Timing Considerations to Minimize Risk
To reduce supine hypertension during sleep:
- Do not give after the evening meal or less than 4 hours before bedtime 1
- Last dose should be no later than 6 PM 1
- Dosing intervals of approximately 4 hours during daytime hours when upright 1
Dose-Dependent Risk
Higher doses carry substantially greater risk of supine hypertension—about 45% of patients experience severe and persistent systolic supine hypertension at 20 mg single doses 1. This reinforces the importance of holding doses when blood pressure is already elevated rather than continuing at standard or higher doses.
The 2017 ACC/AHA syncope guidelines note that use of midodrine may be limited by supine hypertension 2, and the 2020 diabetes guidelines similarly identify supine hypertension as a key limiting factor requiring blood pressure monitoring 3.